HAVCR2 and leukemia: The LSC targets CD44, CD47, CD33, CD96, TIM-3, and CD123 antibodies are undergoing investigation (113, 114); in particular, TIM-3 antibody, MBG-453, which targets LSCs and leukemia blast cells, is used to combinate with HMA, and has shown encouraging response and durability (115).